Different routes of progesterone administration and polycystic ovary syndrome: A review of the literature

References

• Goudas VT, Dumesic DA. Polycystic ovary syndrome. Endocrinol Metab Chin North Am 1997;26:893–912.
   Google Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095–1105.
   PubMed Web of Science ®Google Scholar
• Azziz R. PCOS: a diagnostic challenge. Reprod Biomed Online 2004;8:644–648.
   PubMed Web of Science ®Google Scholar
• Strauss JF 3rd. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann NY Acad Sci 2003;997: 42–48.
   Google Scholar
• Fiad TM, Cunningham SK, McKenna TJ. Role of P deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. Eur J Endocrinol 1996;135:335–339.
   Google Scholar
• Doldi N, Gessi A, Destefani A, Calzi F, Ferrari A. Polycystic ovary syndrome: anomalies in progesterone production. Hum Reprod 1998;13:290–293.
   Google Scholar
• Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF. Acta Obstet Gynecol Scand 2001;80:452–466.
   PubMed Web of Science ®Google Scholar
• Bagchi IC, Li Q, Cheon YP. Role of steroid hormone-regulated genes in implantation. Ann N Y Acad Sci 2001;943:68–76.
   PubMedGoogle Scholar
• Cavagna M, Mantese JC. Biomarkers of endometrial recep-tivity - a review. Placenta 2003;24(Suppl B):539–547.
   Google Scholar
• Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P. Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod 2000;15(Suppl 1):129–148.
   PubMed Web of Science ®Google Scholar
• Mesiano S. Myometrial progesterone responsiveness and the control of human parturition. J Soc Gynecol Investig 2004;11:193–202.
   PubMedGoogle Scholar
• Madsen G, Zakar T, Ku CY, Sanborn BM, Smith R, Mesiano S. Prostaglandins differentially modulate progesterone recep-tor-A and -B expression in human myometrial cells: evidence for prostaglandin-induced functional progesterone withdra-wal. J Clin Endocrinol Metab 2004;89:1010–1013.
   PubMed Web of Science ®Google Scholar
• Neulen J, Breckwoldt M. Placental progesterone, prostaglan-dins and mechanisms leading to initiation of parturition in the human. Exp Clin Endocrinol 1994;102:195–202.
   PubMedGoogle Scholar
• Franks S, Roberts R, Hardy K. Gonadotrophin regimens and oocyte quality in women with polycystic ovaries. Reprod Biomed Online 2003;6:181–184.
   PubMedGoogle Scholar
• Joseph-Home R, Mason H, Batty S, White D, Hillier S, Urquhart M, Franks S. Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum Reprod 2002;17:1459–1463.
   Google Scholar
• Fleming R, McQueen D, Yates RW, Coutts JR. Spontaneous follicular and luteal function in infertile women with oligomenorrhoea: role of luteinizing hormone. Clin Endocri-nol (Oxf) 1995;43:735–739.
   Google Scholar
• Chhabra S, McCartney CR, Yoo RY, Eagleson CA, Chang RJ, Marshall JC. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab 2005;90:2810–2815.
   PubMed Web of Science ®Google Scholar
• Doldi N, Marsiglio E, Destefani A, Gessi A, Merati G, Ferrari A. Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Hum Reprod 1999;14:601–605.
   PubMed Web of Science ®Google Scholar
• Dale PO, Tanbo T, Abyholm T. In-vitro fertilization in infertile women with the polycystic ovarian syndrome. Hum Reprod 1991;6:238–241.
   Google Scholar
• Luboshitzky R, Ishai A, Shen-Or Z, Herer P. Evaluation of the pituitary-adrenal axis in hyperandrogenic women with poly-cystic ovary syndrome. Neuroendocrinol Lett 2003;24:249–254.
   Google Scholar
• Chang RJ. Polycystic ovaries in 2001:physiology and treat-ment. J Gynecol Obstet Biol Reprod (Paris) 2002;31:1S15-1S19.
   Google Scholar
• Woods KS, Reyna R, Azziz R. Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. Fertil Steril 2002;77:1125–1127.
   Google Scholar
• Azziz R. The time has come to simplify the evaluation of the hirsute patient. Fertil Steril 2000;74:870–872.
   Google Scholar
• Anttila L, Koskinen P, Erkkola R, Irjala K, Ruutiainen K. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstet Gynecol Scand 1994;73:634–636.
   Google Scholar
• Homburg R, Weissglas L, Goldman J. Improved treatment for anovulation in polycystic ovarian disease utilizing the effect of progesterone on the inappropriate gonadotrophin release and clomiphene response. Hum Reprod 1988;3:285–288.
   Google Scholar
• Dale PO, Tanbo T, Kjekshus E, Abyholm T. Pregnancy after transfer of cryopreserved embryos in clomiphene citrate resistant polycystic ovarian syndrome. Fertil Steril 1990;53:362–364.
   Google Scholar
• Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 1996;54:59–69.
   PubMed Web of Science ®Google Scholar
• Ritschel WA. Targeting in the gastrointestinal tract: new approaches. Methods Find Exp Clin Pharmacol 1991;13:313–336.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Boyes RN, Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci 1971;60:1338–1340.
   Google Scholar
• Bercovici JP, Darragon T. Administration route of natural sex steroids (estradiol, progesterone, testosterone). Nouv Presse Med 1980;9:179–183.
   Google Scholar
• Mauvais-Jarvis P, Kuttenn F, Wright F. La progestérone administrée par voie percutanée. Ann Endocrinol (Paris) 1975;36:56–62.
   Google Scholar
• Gladtke E, von Hattingberg HM. Problems of rectal applica-tion of drugs. Dtsch Med Wochenschr 1970;95:1494–1496.
   Google Scholar
• Muranishi S. Characteristics of drug absorption via the rectal route. Methods Find Exp Clin Pharmacol 1984;6:763–772.
   PubMed Web of Science ®Google Scholar
• Corbo DC, Liu JC, Chien YW. Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res 1989;6:848–852.
   Google Scholar
• de Boer AG, Moolenaar F, de Leede LG, Breimer DD. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982;7:285–311.
   PubMed Web of Science ®Google Scholar
• Chakmakjian ZH, Zachariah NY. Bioavailability of progester-one with different modes of administration. J Reprod Med 1987;32:443–448.
   PubMed Web of Science ®Google Scholar
• Stovall DW, Van Voorhis BJ, Mattingly KL,, Sparks AET, Chapler FK, Syrop CH. The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study. Fertil Steril 1996;65:986–991.
   Google Scholar
• Miller BE, De Souza MJ, Slade K, Luciano AA. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density. Menopause 2000;7:318–326.
   Google Scholar
• Vaugelade C, Rohmer AC, Burel F, Belleney J, Duclos R, Bunel C. Progesterone freeze-dried systems in sublingual dosage form. Int J Pharm 2001;229:67–73.
   Google Scholar
• Unfer V, Costabile L, Gerli S, Marelli G. Farmacocinetica e farmacodinamica del progesterone: diverse vie di somminis-trazione. In: Ii progesterone. Rome: Verduci Editore; 1999. p 21.
   Google Scholar
• Cicinelli E, Ragno G, Cagnazzo I, Fanelli F Vetuschi C, Schonauer S. Progesterone administration by nasal spray. Fertil Steril 1991;56:139–141.
   PubMed Web of Science ®Google Scholar
• Wuthrich P, Bun P. The transnasal route of drug administra-tion. Aspects of nasal anatomy and physiology. Pharm Acta Hely 1989;64:322–331.
   Google Scholar
• Steege JF, Rupp SL, Stout AL, Bernhisel M. Bioavailability of nasally administered progesterone. Fertil Steril 1986;46:727–729.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Ragno G, Fanelli F, Vetuschi C, Cantatore FP. Nasally-administered progesterone: comparison of ointment and spray formulation. Maturitas 1991;13:313–317.
   Google Scholar
• Cicinelli E, Cignarelli M, Resta L, Scorcia P, Petruzzi D, Santoro G. Effects of the repetitive administration of progesterone by nasal spray in postmenopausal women. Fertil Steril 1993;60:1020–1024.
   Google Scholar
• Cicinelli E, Petruzzi D, Scorcia P, Resta L. Effects of progesterone administered by nasal spray on the human postmenopausal endometrium. Maturitas 1993;18:65–72.
   PubMedGoogle Scholar
• Wattanakumtornkul S, Pinto AB, Williams DB. Intranasal hormone replacement therapy. Menopause 2003;10:88–98.
   Google Scholar
• Williams JK. Contraceptive needs of the perimenopausal woman. Obstet Gynecol Chin North Am 2002;29:575–588.
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Diaz S. The place of progesterone in human contraception. J Steroid Biochem 1987;27:991–994.
   Google Scholar
• McAuley JW, Kroboth FJ, Froboth PD. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy 1996;16:453–457.
   Google Scholar
• Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 2000;73:516–521.
   PubMed Web of Science ®Google Scholar
• Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportion-ality, and comparison with intramuscular progesterone. Fertil Steril 1993;60: 26–33.
   Google Scholar
• Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985;44:622–626.
   PubMed Web of Science ®Google Scholar
• Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Acta Obstet Gynecol Scand 1984;27:94–106.
   Google Scholar
• Ottoson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol 1984;91:1111–1119.
   Google Scholar
• Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 1989;161:948–951.
   Google Scholar
• Chakmakjian ZH, Zachariah NY. Bioavailability of progester-one with different modes of administration. J Reprod Med 1987;32:443–448.
   PubMed Web of Science ®Google Scholar
• Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril 1999;71:614–618.
   PubMed Web of Science ®Google Scholar
• Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, Antoine JM, Zambrano R, Donnez J. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996;11: 2085–2089.
   Google Scholar
• Buvat J, Marcolin G, Guittard C, Herbaut JC, Louvet AL, Dehaene JL. Luteal support after luteinizing hormone releas-ing hormone agonist for in vitro fertilization; superiority of human chorionic gonadotropin over oral progesterone. Fertil Steril 1990;53:490–494.
   PubMed Web of Science ®Google Scholar
• Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185–202.
   PubMed Web of Science ®Google Scholar
• Vanselow W, Dennerstein L, Greenwood KM, de Lignieres B. Effect of progesterone and its 5a and 5fi metabolites or symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996;17: 29–38.
   Google Scholar
• Wilson MA. GABA physiology: modulation by benzodiaze-pines and hormones. Crit Rev Neurobiol 1996;10:1–17.
   Google Scholar
• Perusquia M, Villalon CM. The relaxant effect of sex steroids in rat myometrium is independent of the gamma-amino butyric acid system. Life Sci 1996;58:913–926.
   PubMed Web of Science ®Google Scholar
• Whitehead MI, Townsend PT, Gill DK, Collins WP, Camp-bell S. Absorption and metabolism of oral progesterone. Br Med J 1980;280:825–827.
   Google Scholar
• Antonipillai J, Moghissi E, Hawks D, Schneider T, Horton R. The origin of plasma deoxycorticosterone in men and in women during the menstrual cycle. J Chin Endocrinol Metab 1983;56:93–98.
   Google Scholar
• Casey ML, MacDonald PC. Formation of deoxycorticoster-one from progesterone in extraadrenal tissues: demonstration of steroid 21-hydroxylase activity in human aorta. J Chin Endocrinol Metab 1982;55:804–806.
   Google Scholar
• Winkel CA, Parker CR Jr, Simpson ER, MacDonald PC. Production rate of deoxycorticosterone in women during follicular and luteal phases of ovarian cycle: the role of extraadrenal 21-hydroxylation of circulation progesterone in deoxycorticosterone production. J Chin Endocrinol Metab 1980;51:1354–1358.
   PubMed Web of Science ®Google Scholar
• Adlercreutz H, Martin F. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem 1980;13:231–244.
   PubMedGoogle Scholar
• Landau RL,, Lugibihl K. Inhibition of the sodium retaining influence of aldosterone by progesterone. J Chin Endocrinol Metab 1958;18:1237–1245.
   PubMed Web of Science ®Google Scholar
• Sharp GWG, Komack CL, Leaf A. Studies on the binding of aldosterone in the toad bladder. J Chin Invest 1966;45:450–459.
   Google Scholar
• Wambach G, Higgins I. Antimineralocorticoid action of progesterone in the rat: correlation of the effect on electrolyte excretion and interaction with renal mineralocorticoid recep-tors. Endocrinology 1978;102:1686–1693.
   PubMed Web of Science ®Google Scholar
• Fanchin R, de Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol 1997;90:396–401.
   PubMed Web of Science ®Google Scholar
• Von Eye Corleta H, Capp E, Cardoso Ferreira MB. Pharmacokinetics of natural progesterone vaginal suppository. Gynecol Obstet Invest 2004;58:105–108.
   PubMed Web of Science ®Google Scholar
• Alam V, Vega M, Risquez F. Luteal phase support. Reprod Biomed Online 2001;3:250–262.
   Google Scholar
• Weckstein LN, Jacobson A, Galen D, Hampton K, Ivani K, Andres J. Improvement of pregnancy rates with oocytes donation in older recipients with the addition of progesterone vaginal suppositories. Fertl Steril 1993;60:573–575.
   Google Scholar
• Maddocks S, Hahn P, Moller F, Reid RL. A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am J Obstet Gynecol 1986;154:573–581.
   PubMed Web of Science ®Google Scholar
• Kalund-Jensen H, Myren CJ. Vaginal absorption of oestradiol and progesterone. Maturitas 1984;6:359–367.
   Google Scholar
• Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000;6:139–148.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Borraccino V, Petruzzi D, Mazzotta N, Cerundolo ML, Schonauer LM. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progester-one in an oil-based solution to postmenopausal women. Fertil Steril 1996;65:860–862.
   PubMed Web of Science ®Google Scholar
• Norman TR, Morse C, Dennerstein L. Comparative bioavail-ability of orally and vaginally administered progesterone. Fertil Steril 1991;56:1034–1039.
   PubMed Web of Science ®Google Scholar
• Perino M, Brigandi FG, Abate FG, Costabile L, Balzano E, Abate A. Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Chin Exp Obstet Gynecol 1997;24:228–231.
   Google Scholar
• Abate A, Perin° M, Abate FG, Brigandi A, Costabile L, Manti F. Intramuscular versus vaginal administration of progester-one for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Chin Exp Obstet Gynecol 1999;26:203–206.
   PubMedGoogle Scholar
• Sauer MV, Stein AL, Paulson RJ, Moyer DL. Endometrial responses to various hormone replacement regimens in ovarian failure patients preparing for embryo donation. Int J Gynecol Obstet 1991;35:61–68.
   Google Scholar
• Archer DF, Fahy GE, Viniegra-Sibal A, Anderson FD, Snipes W, Foldesy RG. Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol 1995;173:471–477.
   Google Scholar
• Villanueva B, Casper RF, Yen SCS. Intravaginal administra-tion of progesterone enhanced absorption after estrogen treatment. Fertil Steril 1981;35:433–437.
   Google Scholar
• Erny R, Simoncini C, Chastelliere N, de Ligneres B. Variation de la progestérone plasmatique induites par l'administration vaginale d'Utrogestan. J Gynecol Biol Reprod 1989;18:229–234.
   Google Scholar
• Penzias AS, Alper MM. Luteal support with vaginal micro-nized progesterone gel in assisted reproduction. Reprod Biomed Online 2003;6:287–295.
   PubMedGoogle Scholar
• Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective randomized study. Minerva Ginecol 2001;53:297–301.
   Google Scholar
• Lightman A, Kol S, Itskovitz-Eldor J. A prospective rando-mized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Hum Reprod 1999;14:2596–2599.
   Google Scholar
• Can KJ. ABC of endocrinology. I. Hormones in general. Lancet 1970;1:763–765.
   Google Scholar
• Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Sterteghem AC. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum Reprod 1992;7:168–175.
   Google Scholar
• Nillius SJ, Johansson EDB. Plasma progesterone levels after intramuscular or rectal administration of progesterone. Acta Obstet Gynecol Scand 1971;50:46.
   Google Scholar
• Buckler HM, Bangah M, Healy DL, Burger HG. Vaginal progesterone administration in physiological doses normalizes raised luteinizing hormone levels in patients with polycystic ovarian syndrome. Gynecol Endocrinol 1992;6:275–282.
   PubMed Web of Science ®Google Scholar
• Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Chin Endocrinol Metab 1998;83:582–590.
   PubMed Web of Science ®Google Scholar
• Balasch J, Fabregues F, Casamitjana R, Penarrubia J, Vanrell JA. A pharmacokinetic and endocrine comparison of recom-binant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome. Reprod Biomed Online 2003;6:296–301.
   Google Scholar
• Urman B, Tiras B, Yakin K. Assisted reproduction in the treatment of polycystic ovarian syndrome. Reprod Biomed Online 2004;8:419–430.
   Google Scholar